What Is BPC-157?

Where the BPC-157 sequence comes from

Laboratory papers describe BPC-157 as a pentadecapeptide, a chain of 15 amino acids, that reproduces part of the sequence of body protection compound (BPC), a protein the authors describe as discovered in and isolated from human gastric juice. The material used in research is made by chemical synthesis, and its sequence is the fragment rather than the full parent protein.In vitro · PMID 21030672In vitro · PMID 25415472

A 2003 rat study published the sequence as GEPPPGKPADDAGLV and the molecular weight as 1419. That paper also stated that the peptide was dissolved in saline with no carrier added, and it described the molecule as stable, which is why many papers call it the stable gastric pentadecapeptide. Code names such as PL 14736 and PLD-116 appear in the older literature for the same sequence.Animal study · PMID 14554208Animal study · PMID 20225319

A 2019 review of the musculoskeletal literature noted two structural facts about the field itself: the majority of studies had been performed on small rodent models, and over the previous two decades only a handful of research groups had carried out in-depth studies of the peptide. Both points shape how the findings below should be read.Review · PMID 30915550

What the tendon and ligament studies measured

In the 2003 rat study, the right Achilles tendon was transected and assessed on days 1, 4, 7, 10 and 14. The authors measured load of failure, load of failure per area, Young's modulus of elasticity and an Achilles functional index, and they examined the tissue under the microscope for fibroblasts, reticulin and collagen. They reported higher biomechanical values and higher functional index scores in the peptide group than in saline controls. In the cell-culture arm of the same paper, the peptide had no effect on the growth of cultured tendocytes on its own, but it opposed the growth-inhibiting effect of 4-hydroxynonenal.Animal study · PMID 14554208

A 2011 study used tendon fibroblasts taken from rat Achilles tendon. Proliferation, measured by MTT assay, was not directly affected by BPC-157. What changed was the outgrowth of fibroblasts from tendon explants, cell survival under hydrogen peroxide stress, migration in a transwell assay, and cell spreading. The authors measured rising phosphorylation of FAK and paxillin, with total protein amounts unaltered, and proposed the FAK-paxillin pathway as the mechanism.In vitro · PMID 21030672

A follow-up study from the same group ran a cDNA microarray on rat tendon fibroblasts and found the growth hormone receptor among the most up-regulated genes. Receptor mRNA and protein rose with time and peptide concentration. Adding growth hormone to the exposed cells raised proliferation by MTT assay and PCNA expression, and activated Janus kinase 2, the downstream signal of that receptor.In vitro · PMID 25415472

Not every tendon result was positive. In a 2026 rat study, 32 animals had the Achilles tendon transected and repaired, and were split into four groups of eight: control, BPC-157, TB-500 and the two combined. At four weeks, maximum load to failure was higher than control in both single-peptide groups, but the difference reached statistical significance only for TB-500. The BPC-157 group showed numerically lower Bonar and Movin histology scores without statistical significance for total scores, and the combination showed no additional effect over either peptide alone.Animal study · PMID 42542926

Blood vessels and nitric oxide signaling

The most frequently proposed mechanism involves blood-vessel formation. In a 2017 study, BPC-157 increased vessel density in the chick chorioallantoic membrane assay and in an endothelial tube-formation assay. In rats with hind limb ischemia, laser Doppler scanning recorded faster recovery of blood flow, and histology counted more vessels. In cultured human vascular endothelial cells, the peptide raised mRNA and protein for the receptor VEGFR2 but not for its ligand VEGF-A, and it activated the VEGFR2-Akt-eNOS pathway.Animal study · PMID 27847966

A 2020 study on isolated rat aorta measured a concentration-dependent widening of the vessel that depended on the endothelium and was blocked by L-NAME or hemoglobin, both of which interfere with nitric oxide. In endothelial cells, the peptide induced nitric oxide generation, increased phosphorylation of Src, Cav-1 and eNOS, and reduced the binding between Cav-1 and eNOS.In vitro · PMID 33051481

The cell-culture findings are not uniform across laboratories. A 2009 study that correlated angiogenesis with VEGF expression reported no direct angiogenic effect of BPC-157 on cell cultures. In the same work, immunohistochemistry for VEGF, CD34 and factor VIII in crushed and transected rat muscle and tendon showed modulated angiogenesis in the peptide groups, leading the authors to tie the vessel effect to the injured tissue in vivo rather than to cells in a dish.Animal study · PMID 20388964

Stomach and skin models

The gastric literature is where the compound's name comes from. In a 2020 study in Sprague Dawley rats, ulcers were first induced with acetic acid and then allowed to resolve before clopidogrel was given to provoke recurrence. The authors recorded ulcer recurrence, inflammation and endoplasmic reticulum stress-related apoptosis in the gastric lining after clopidogrel. In rats that also received BPC-157, those markers were attenuated, and blocking nitric oxide with L-NAME weakened the effect.Animal study · PMID 33376304

In a 2015 rat model of alkali burns to the skin, topical BPC-157 was associated with faster wound closure, and histology on the 18th day after wounding showed more granulation tissue, re-epithelialization and collagen deposition than in the model control group. In cultured human umbilical vein endothelial cells, the peptide raised proliferation, migration, VEGF-a expression and tube formation, and it altered phosphorylation of ERK1/2 and its downstream targets c-Fos, c-Jun and Egr-1.Animal study · PMID 25995620

What has been recorded in people

A PRISMA-compliant systematic review registered with PROSPERO searched Embase, PubMed, the Cochrane Library and ClinicalTrials.gov up to 1 June 2026. Three studies met its criteria, with 30 participants in total: a retrospective study of knee pain (n=16), a retrospective pilot study in interstitial cystitis (n=12) and a prospective pilot safety study (n=2). None had a control group. The reviewers judged all three to be of poor methodological quality and rated the overall certainty of evidence as very low because of serious risk of bias, indirectness and imprecision.Review · PMID 42885452

The smallest of those studies enrolled 2 adults, aged 58 and 68, and recorded blood work and vital signs at each visit across three days. The authors reported no measurable effects on the tested biomarkers of the heart, liver, kidneys or thyroid, or on blood glucose, and no side effects were reported. With two participants and no comparison group, the study cannot estimate how often adverse events occur.Human trial · PMID 40131143

An earlier systematic review, searching to June 2024, screened 544 articles and included 36 studies: 35 preclinical and 1 clinical. It found no clinical safety data and noted that the peptide lacked US Food and Drug Administration approval and was banned in professional sports.Review · PMID 40756949

How to read the BPC-157 evidence

Three features of this literature matter more than any single result. First, most data come from rats, and the 2019 review stressed that efficacy had not been confirmed in people. Second, a small number of research groups produced most of the work, so independent replication is thin. Third, the cell results disagree on whether the peptide acts directly on cultured cells or only in injured tissue, as the 2009 and 2017 vessel studies show.Review · PMID 30915550Animal study · PMID 20388964Animal study · PMID 27847966

The one independent rat tendon study published in 2026 found that BPC-157 did not reach statistical significance on its main biomechanical or total histology scores, while an older study from the originating group reported full recovery of the transected tendon. Differences in design, duration and laboratory may explain the gap, but until controlled studies in people exist, the 2026 review's verdict of very low certainty is the most accurate summary of what is known.Animal study · PMID 42542926Animal study · PMID 14554208Review · PMID 42885452

The studies at a glance

Key BPC-157 studies, by model. Results are as reported in each paper's abstract.

Frequently asked questions